Publications by the researcher in collaboration with JOSÉ LUIS MARCO CONTELLES (39)

2022

  1. Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout

    Journal of Medicinal Chemistry, Vol. 65, Núm. 8, pp. 6250-6260

2020

  1. Highlights of ASS234: A novel and promising therapeutic agent for Alzheimer's disease therapy

    Neural Regeneration Research, Vol. 15, Núm. 1, pp. 30-35

  2. In Vitro and in Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases

    ACS Chemical Neuroscience, Vol. 11, Núm. 22, pp. 3793-3801

2019

  1. Quinoxalinetacrine QT78, a cholinesterase inhibitor as a potential ligand for Alzheimer’s disease therapy

    Molecules, Vol. 24, Núm. 8

2018

  1. Analysis of gene expression profiles of CR80, a neuroprotective 1,8-Naphthyridine

    Future Medicinal Chemistry, Vol. 10, Núm. 11, pp. 1289-1300

  2. In silico assessment of the metabolism and its safety significance of multitarget propargylamine ASS234

    CNS Neuroscience and Therapeutics

  3. Modulation of Heat Shock Response Proteins by ASS234, Targeted for Neurodegenerative Diseases Therapy

    Chemical Research in Toxicology, Vol. 31, Núm. 9, pp. 839-842

  4. Neuroinflammation Signaling Modulated by ASS234, a Multitarget Small Molecule for Alzheimer's Disease Therapy

    ACS Chemical Neuroscience, Vol. 9, Núm. 12, pp. 2880-2885

2017

  1. 5-Methyl-: N -(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5 H -indolo[2,3- b] quinolin-11-amine: A highly potent human cholinesterase inhibitor

    MedChemComm, Vol. 8, Núm. 6, pp. 1307-1317

  2. Corrigendum: Melatonin and nitrones as potential therapeutic agents for stroke [Front. Aging Neurosci., 8 (2016) (281)] DOI:10.3389/fnagi.2016.00281

    Frontiers in Aging Neuroscience

  3. Ischemic brain injury: New insights on the protective role of melatonin

    Free Radical Biology and Medicine, Vol. 104, pp. 32-53

  4. Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration

    Future Medicinal Chemistry, Vol. 9, Núm. 8, pp. 765-780

  5. Multitarget-Directed Antioxidants as Therapeutic Agents: Putting the Focus on the Oxidative Stress

    Design of Hybrid Molecules for Drug Development (Elsevier Inc.), pp. 5-46

  6. Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases

    Angewandte Chemie - International Edition, Vol. 56, Núm. 41, pp. 12765-12769

  7. Recent developments on multi-target-directed tacrines for alzheimer’s disease. I. The pyranotacrines

    Current Topics in Medicinal Chemistry, Vol. 17, Núm. 31, pp. 3328-3335

  8. The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease

    Journal of Psychiatry and Neuroscience, Vol. 42, Núm. 1, pp. 59-69

2016

  1. ASS234, as a new multi-target directed propargylamine for Alzheimer's disease therapy

    Frontiers in Neuroscience, Vol. 10, Núm. JUN

  2. Melatonin and nitrones as potential therapeutic agents for stroke

    Frontiers in Aging Neuroscience, Vol. 8, Núm. NOV

  3. Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices

    NeuroToxicology, Vol. 57, pp. 61-68

  4. Synthesis and biological evaluation of heterocyclic privileged medicinal structures containing (benz)imidazole unit

    Monatshefte fur Chemie, Vol. 147, Núm. 12, pp. 2209-2220